https://www.retatruti.de/en 2026-04-03T19:55:43.808Z weekly 1 https://www.retatruti.de/de 2026-04-03T19:55:43.808Z weekly 1 https://www.retatruti.de/en/articles 2026-04-03T19:55:43.808Z monthly 0.7 https://www.retatruti.de/de/articles 2026-04-03T19:55:43.808Z monthly 0.7 https://www.retatruti.de/en/where-to-buy-research-grade-retatrutide 2026-04-03T19:55:43.808Z monthly 0.7 https://www.retatruti.de/de/where-to-buy-research-grade-retatrutide 2026-04-03T19:55:43.808Z monthly 0.7 https://www.retatruti.de/en/impressum 2026-04-03T19:55:43.808Z monthly 0.7 https://www.retatruti.de/de/impressum 2026-04-03T19:55:43.808Z monthly 0.7 https://www.retatruti.de/en/articles/retatrutide-12mg-maintenance-dose-phase-3-results 2026-03-23T00:00:08.560Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-12mg-maintenance-dose-phase-3-results 2026-03-23T00:00:08.750Z monthly 0.8 https://www.retatruti.de/en/articles/is-retatrutide-fda-approved 2026-03-17T18:00:06.695Z monthly 0.8 https://www.retatruti.de/de/articles/is-retatrutide-fda-approved-what-to-know 2026-03-17T18:00:06.695Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-side-effects-skin-tightening-and-sagging-prevention 2026-03-23T06:00:06.641Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-side-effects-skin-tightening-and-sagging-prevention 2026-03-23T06:00:07.014Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-nda-submission-late-2026-fda-pdufa-date-october-2027-timeline 2026-03-30T03:00:23.992Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-nda-submission-late-2026-fda-pdufa-date-october-2027-timeline 2026-03-30T03:00:24.215Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-approval-tracker-fda-ema-tga 2026-03-18T06:00:06.662Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-approval-tracker-fda-ema-tga-status-2025 2026-03-18T06:00:06.662Z monthly 0.8 https://www.retatruti.de/en/articles/is-retatrutide-legal-in-us 2026-02-23T16:00:05.080Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-pdufa-date-2027 2026-03-09T03:00:34.735Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-legal-access-guide 2026-02-27T14:39:11.434Z monthly 0.8 https://www.retatruti.de/de/articles/rechtlicher-status-von-retatrutide-2025-noch-in-der-klinischen-erprobung 2026-02-27T14:39:11.434Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-phase-2-results-explained 2026-02-25T03:05:10.118Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-ergebnisse-der-phase-2-studien 2026-02-25T03:05:10.118Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-without-prescription-legal-status-and-risks 2026-03-18T12:00:08.517Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-without-a-prescription-legal-status-and-risks 2026-03-18T12:00:08.841Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-vs-wegovy-vs-zepbound 2026-02-27T14:38:25.026Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-im-vergleich-zu-wegovy-wirksamkeit-sicherheit-und-zulassungsstatus 2026-02-27T14:38:25.026Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-muscle-preservation-during-weight-loss 2026-03-05T00:44:03.257Z monthly 0.8 https://www.retatruti.de/en/articles/bimagrumab-and-retatrutide-stack-for-zero-muscle-loss 2026-03-06T03:00:34.581Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-4mg-maintenance-dose-phase-3-strategy 2026-03-06T21:00:34.636Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-4mg-maintenance-dose-phase-3-strategy 2026-03-06T21:00:34.636Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-compounding-legality-fda-warnings-2026 2026-03-06T09:00:35.227Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-compounding-legality-fda-warnings-2026 2026-03-06T09:00:35.430Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-price-and-cost-faq 2026-03-18T09:00:07.986Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-price-and-cost-faq-what-to-expect-and-alternatives 2026-03-18T09:00:07.986Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-vs-semaglutide-for-pcos-weight-loss 2026-03-09T09:00:34.670Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-vs-semaglutide-for-pcos-weight-loss 2026-03-09T09:00:34.966Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-cardiovascular-risk-reduction-triumph-3-trial 2026-03-23T03:00:06.686Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-cardiovascular-risk-reduction-triumph-3-trial 2026-03-23T03:00:07.435Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-complete-response-letter-crl-risks-what-happens-if-fda-denies-approval 2026-03-30T03:00:24.372Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-complete-response-letter-crl-risks-what-happens-if-fda-denies-approval 2026-03-30T03:00:24.522Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-mash-liver-fat-reduction-phase-3-benefits 2026-03-13T12:00:34.975Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-fda-category-2-peptide-compounding-2026-changes 2026-03-16T03:00:34.772Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-fda-category-2-peptide-compounding-2026-changes 2026-03-16T03:00:34.983Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-triumph-1-trial-results-80-week-weight-loss 2026-03-23T00:00:07.542Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-triumph-1-trial-results-80-week-weight-loss 2026-03-23T00:00:07.847Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-advisory-committee-dysesthesia-vote-outcome-2027 2026-03-16T09:00:34.726Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-availability-and-release-date 2026-03-18T09:00:07.602Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-availability-and-release-date-latest-updates 2026-03-18T09:00:07.602Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-manufacturing-scale-up-timeline-2028-pharmacy-availability-supply-chain 2026-03-30T03:00:23.736Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-manufacturing-scale-up-timeline-2028-pharmacy-availability-supply-chain 2026-03-30T03:00:23.736Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-dysesthesia-advisory-committee-approval-odds-fda-decision-2027 2026-03-30T06:00:23.564Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-dysesthesia-advisory-committee-approval-odds-fda-decision-2027 2026-03-30T06:00:23.564Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-dysesthesia-causes-and-management-phase-3 2026-03-23T03:00:07.697Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-dysesthesia-causes-and-management-phase-3 2026-03-23T03:00:07.697Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-advisory-committee-dysesthesia-review-2027-risks 2026-03-13T03:00:35.043Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-advisory-committee-dysesthesia-review-2027-risks 2026-03-13T03:00:36.076Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-dysesthesia-20-percent-patients-fda-advisory-committee-approval-risk 2026-03-18T03:00:06.698Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-dysesthesia-20-percent-patients-fda-advisory-committee-approval-risk 2026-03-18T03:00:06.698Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-triumph-4-osteoarthritis-womac-score-67-percent-pain-reduction-mechanism 2026-03-30T06:00:24.625Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-triumph-4-osteoarthritis-womac-score-67-percent-pain-reduction-mechanism 2026-03-30T06:00:24.625Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-breakthrough-therapy-designation-priority-review-status-2027-approval-acceleration 2026-03-30T00:00:25.836Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-breakthrough-therapy-designation-priority-review-status-2027-approval-acceleration 2026-03-30T00:00:25.836Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-for-obstructive-sleep-apnea-triumph-trial-results 2026-03-23T00:00:08.323Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-for-obstructive-sleep-apnea-triumph-trial-results 2026-03-23T00:00:08.323Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-biohacking-stack-with-tesamorelin-for-fat-loss 2026-03-23T03:00:07.930Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-biohacking-stack-with-tesamorelin-for-fat-loss 2026-03-23T03:00:07.930Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-dysesthesia-side-effects-explained 2026-03-18T15:00:07.100Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-dysesthesia-side-effects-explained 2026-03-18T15:00:07.100Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-safety-profile-phase-3-discontinuations-bmi-correlation 2026-03-18T21:00:06.824Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-safety-profile-phase-3-discontinuations-bmi-correlation 2026-03-18T21:00:06.824Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-insurance-coverage-2026-medicare-obesity 2026-03-23T03:00:08.064Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-insurance-coverage-2026-medicare-obesity 2026-03-23T03:00:08.064Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-dysesthesia-management-strategies-peripheral-neuropathy-prevention 2026-03-30T06:00:23.766Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-dysesthesia-management-strategies-peripheral-neuropathy-prevention 2026-03-30T06:00:23.925Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-vs-tirzepatide-for-non-diabetic-weight-loss 2026-03-18T15:00:07.530Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-vs-tirzepatide-for-non-diabetic-weight-loss 2026-03-18T15:00:07.530Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-priority-review-designation-glp-1-obesity-fda 2026-03-23T06:00:07.195Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-priority-review-designation-glp-1-obesity-fda 2026-03-23T06:00:07.478Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-compounding-pharmacy-cost-comparison-2026-insurance-coverage-gaps 2026-03-30T06:00:24.164Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-compounding-pharmacy-cost-comparison-2026-insurance-coverage-gaps 2026-03-30T06:00:24.164Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-biohacking-stack-with-bimagrumab-for-knee-osteoarthritis 2026-03-30T00:00:23.912Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-biohacking-stack-with-bimagrumab-for-knee-osteoarthritis 2026-03-30T00:00:24.502Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-vs-mazdutide-phase-3-weight-loss-comparison-china-us 2026-03-30T00:00:25.053Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-vs-mazdutide-phase-3-weight-loss-comparison-china-us 2026-03-30T00:00:25.592Z monthly 0.8 https://www.retatruti.de/en/articles/retatrutide-complete-response-letter-risks-after-nda-submission-2026 2026-03-23T06:00:07.686Z monthly 0.8 https://www.retatruti.de/de/articles/retatrutide-complete-response-letter-risks-after-nda-submission-2026 2026-03-23T06:00:07.686Z monthly 0.8